RET融合遗传基因的全球市场:市场规模，目标人群，竞争情形，市场预测-2034年

美国研究公司DelveInsight发布的 "全球RET融合基因市场－市场规模、目标族群、竞争格局及2034年预测" 报告，详细介绍了美国、四个欧盟国家（德国、法国、义大利和西班牙）、英国和日本的RET融合基因、潜在患者群体、竞争格局和未来市场趋势。

"RET融合基因市场报告" 深入分析了针对RET融合基因患者的现有治疗方法、已获批和新兴的RET融合基因、个体疗法的市场份额、RET融合基因治疗的目标患者群体，以及2020年至2034年七个主要国家按疗法和适应症划分的当前和预测RET融合基因市场规模。本报告还涵盖了目前未满足的需求以及将新类别纳入治疗模式的挑战、新RET融合基因可用性和接受度的地区差异，以及对RET融合基因报销的洞察，从而识别最佳机会并评估市场潜力。

目标地区

• 美国
• 欧盟四国（德国、法国、义大利、西班牙）、英国
• 日本

研究期间：2020-2034

RET融合基因概述

本部分提供详细信息，涵盖抑制剂的研发历程，涵盖从突变和蛋白表达发现到进入临床开发阶段以及未来商业潜力的各个方面。本部分深入探讨了抑制剂正在开发的各种适应症，并深入了解了这些抑制剂可能针对的潜在患者群体。此外，本部分也简要概述了针对每个目标适应症的现有治疗方案。

RET 融合基因在临床上的应用

本节详细介绍了目前治疗模式中针对所有潜在适应症的现有局部和全身治疗方案，大多数製药公司正在积极评估抑制剂。分析新型 RET 融合基因的潜力至关重要，因为这些基因可能会改变目前的临床实践指南，尤其是在实际应用中。

本节也涵盖了生物标记检测在不同疾病阶段的相关性和重要性。此外，还需要了解的是，由于成本、可近性、报销以及指南不推荐等问题，此类检测在常规临床实践中的实施在不同国家/地区存在差异。

RET 融合基因药物章节

RET 融合基因报告的药物章节对市售和后期（III 期和 II 期）疗法进行了深入分析。它还可以帮助您了解RET融合基因临床试验的详细资讯、药理作用、RET融合基因相关协议与合作、审批时间表、专利详情、优缺点以及最新的新闻和新闻稿。

已上市RET融合基因疗法

"RET融合基因疗法" 部分提供了已核准疗法的详细药物概况。这包括临床开发活动、上市日期、监管里程碑以及安全性和有效性数据的资讯。

新兴RET融合基因疗法

除了以表格形式呈现的全面的RET融合基因竞争格局外， "新兴KRAS抑制剂" 章节还提供了针对各种适应症的中后期临床开发的新兴RET融合基因的产品详情和其他开发活动。

药物类别洞察

"药物类别洞察" 部分提供了关于RET融合基因这一类别的全面资讯。这包括对该类别及其在特定疾病治疗中的作用的广泛概述。洞察涵盖了RET融合基因的既往临床开发、其作用机制、亚型以及未来的商业前景。此外，我们还详细介绍了此类药物的当前趋势、挑战和未来前景。

RET融合基因市场展望

本节详细介绍了抑制剂临床开发活动启动后RET融合基因市场的变化动态。它还对该领域主要公司正在开发的所有疗法进行了详细的总结和比较。本节重点介绍了一种疗法相对于另一种疗法的优势，并根据安全性和有效性数据的可用性、每次试验的患者人数以及试验纳入标准等参数进行了评估。它强调了开发这些标靶疗法的重要性，以及这些疗法取得商业成功以实现医生和患者期望的治疗目标的必要性。它还总结了活跃于该领域的早期进入者。

RET 融合基因疗法的渗透率

本节重点介绍已上市并预计将于 2020 年至 2034 年期间上市的潜在 RET 融合基因药物的吸收率，具体取决于竞争格局、安全性和有效性数据以及进入顺序。重要的是，在关键试验和验证性试验中评估新型疗法的大型公司必须谨慎选择合适的对照药物，以最大限度地提高获得积极监管反馈的机会，从而获得批准、顺利上市并快速推广。

RET 融合基因管线开发活动

本报告深入分析了处于 III 期和 II 期的各种候选疗法。本报告也分析了参与标靶药物开发的关键参与者。

RET 融合基因管线开发活动

本报告提供了与 RET 融合基因相关的合作、收购、授权和专利细节的全面资讯。

关键意见领袖 (KOL) 观点

为了了解当前和未来的市场趋势，我们透过一手资料和二手资料研究，咨询了领先的医生、治疗领域研究人员和其他行业专家，以填补数据空白并验证我们的二手资料研究。我们联繫了超过 25 位关键意见领袖，以深入了解 RET 融合基因融入不断发展的治疗方法、患者对传统疗法的依赖性、患者对治疗转换的接受度、药物吸收以及药物可及性挑战。

定性分析

我们使用各种方法进行定性和市场情报分析，包括 SWOT 分析和分析师洞察。 SWOT 分析提供了疾病诊断、患者认知度、竞争格局、成本效益和区域治疗可及性方面的优势、劣势、机会和威胁。这些发现是基于我们分析师的判断以及对成本分析和现有及不断发展的治疗模式的评估。

市场准入与报销

本节深入分析了标准医疗费用评估 (HTA) 定价、2024 年的最新改革以及七个主要国家报销流程的变化。例如，美国采用多付款人模式定价药品，但近期的联邦立法，例如 "降低通膨法案" 中关于处方药价格改革的条款，已显着改变了某些联邦体系中的药品定价体系，目前该体係正在经历重大变革。同时，德国的市场准入系统与许多其他国家采用的体係不同，因为新药上市时无需获得定价和报销批准。

本节也提供了已获批准疗法的报销（如有）的详细资讯。

范围：

• 本报告涵盖关键事件、摘要整理、目标族群、流行病学、市场预测、患者人口统计资讯以及各种生物标记检测率。
• 此外，本报告全面描述了当前和新兴疗法，并深入了解了RET融合基因的潜在患者群体。
• 本报告详细回顾了RET融合基因市场，包括历史和预测市场规模、按疗法划分的市场份额、详细的预测假设以及我们方法的原理。
• 透过SWOT分析、专家见解/KOL观点和治疗偏好，帮助您在製定业务策略方面占优势，从而塑造和推动7个主要国家/地区的RET融合基因市场。
• 依疗法和适应症提供抑制剂的市场规模。

目录

第1章 重要的洞察

第2章 报告书的简介

第3章 RET融合遗传基因的摘要整理

第4章 主要事件

第5章 RET融合遗传基因市场概要

• 2023年的RET融合遗传基因的市场占有率(%)分布，各治疗法
• 2034年的RET融合遗传基因的市场占有率(%)分布，各治疗法

第6章 背景和概要

第7章 目标族群

第8章 RET融合遗传基因的成药

第9章 RET融合遗传基因的新药

第10章 分析RET融合遗传基因:主要7个国家

• 主要调查结果
• 市场预测
• 主要的市场预测的前提条件
• 主要7个国家的RET融合遗传基因的整体市场规模
• 美国市场
• EU4个国家和英国市场
• 日本市场

第11章 未满足需求

第12章 SWOT分析

第13章 KOL的见解

第14章 市场进入与偿付

• 美国
• EU4个国家和英国
• 日本

第15章 附录

第16章 DelveInsight的能力

第17章 免责声明

第18章 关于DelveInsight

DelveInsight's "RET Fusion Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report delivers an in-depth understanding of RET Fusion, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

The RET Fusion market report provides insights around existing treatment practices in patients with RET Fusion, approved (if any) and emerging RET Fusion, market share of individual therapies, patient pool eligible for treatment with RET Fusion, along with current and forecasted 7MM RET Fusion market size from 2020-2034 by therapies and by indication. The report also covers current unmet needs and challenges while incorporating new classes in treatment paradigm, variations in accessibility and acceptability of new RET Fusion in different geographies, along with insights on RET Fusion pricing reimbursements to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain), and the UK
• Japan

Study Period: 2020-2034

RET Fusion Overview

This segment will provide detailed information beginning with the inhibitor journey from discovery of the mutation or protein expression to its entry into clinical development followed by its upcoming commercial potential. This segment will dive into the different indications for which the inhibitor is being developed for, which would further give insights on the potential addressable patient population. Moreover, this segment will also give a brief overview around the existing treatment paradigm of the target indications.

RET Fusion in Clinical Practice

This section will give in depth information about the existing local and systemic options in the current treatment paradigm of all the potential indications, in which most of the pharmaceutical companies are actively evaluating their inhibitors. Potential of the emerging RET Fusion in changing the current clinical practice guidelines is crucial to analyze especially when it comes to real world scenario.

It will also include the relevance and importance of incorporation of biomarker testing at varying stages of the disease. It is also important to understand that implementing such tests in routine clinical practice is not uniform in different countries due to issues such as cost, accessibility, reimbursement and non-recommendation in guidelines.

RET Fusion Drug Chapters

The drug chapter segment of the RET Fusion report encloses a detailed analysis of marketed therapies and late-stage (Phase III and Phase II) therapies. It also helps understand the RET Fusion clinical trial details, pharmacological action, agreements and collaborations related to RET Fusion, their approval timelines, patent details, advantages and disadvantages, latest news and press releases.

RET Fusion Marketed Drugs

The RET Fusion marketed drug section will provide detailed drug profiles of already approved therapies. Information around clinical development activities, launch timing, regulatory milestones along with safety and efficacy data of the therapy will be included.

RET Fusion Emerging Drugs

Apart from a comprehensive RET Fusion competitive landscape in tabular form, the emerging KRAS Inhibitor chapters provides the product details and other development activities of the emerging RET Fusion under the late and mid-stage of clinical development for various indications.

Drug Class Insights

The Drug Class Insights section will provide comprehensive information on RET Fusion as a class. This will include a broad overview of the class and its role in treating specific conditions. Insights may cover the historical clinical development of RET Fusion, their mechanism of action, their subtypes and future commercial prospects. Additionally, the section will provide detailed information about current trends, challenges, and future prospects for this class of drugs.

RET Fusion Market Outlook

This section will include details on changing RET Fusion market dynamics post initiation of clinical development activities of the inhibitor. It will also provide a detailed summary and comparison of all the therapies being developed by leading players in this space. This section will highlight the advantages of one therapy over the other after assessment based on parameters such as data availability in the form of safety and efficacy, number of patients enrolled in each trial, and trial's inclusion criteria. There will be a Key focus on the importance of development and need for the commercial success of these targeted therapies to achieve treatment goals that physicians and patients are looking for. It will also sum up all the early stage players active in this space.

RET Fusion Drugs Uptake

This section focuses on the uptake rate of potential RET Fusion already launched and expected to be launched in the market during 2020-2034, which depends on the competitive landscape, safety, efficacy data, and order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

RET Fusion Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

RET Fusion Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for RET Fusion.

KOL Views

To keep up with current and future market trends, we incorporate Key physicians, Therapy Area Researcher's, and other Industry Experts' opinions working in the domain through primary research to fill in the data gaps and validate our secondary research. 25+ Key Opinion Leaders (KOLs) were contacted for insights on RET Fusion' incorporation in the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility.

Qualitative Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Analyst views. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the cost analysis and existing and evolving treatment landscape.

Market Access and Reimbursement

This section will include insights around the standard HTA pricing, recent reformations in 2024 and modifications in reimbursement process in the 7MM. For example, In the United States, a multi payer model exists when it comes to drug pricing regime, which is currently undergoing significant changes, with recent federal legislation, such as the Prescription Drug Pricing Reform provisions of the Inflation Reduction Act, significantly altering the pricing regime under certain federal programs. Whereas in Germany, the market access differs from the systems followed in many other countries as no pricing and reimbursement approval is required during launch of a new therapy.

Moreover, this section will also provide details on reimbursement of approved therapy, if any.

Scope of the Report:

• The report covers a segment of key events, an executive summary, target patient pool, epidemiology and market forecasts, information around patient journey and varying biomarker testing rates
• Additionally, an all-inclusive account of the current and emerging therapies drug chapters, insights on RET Fusion addressable patient pool
• A detailed review of the RET Fusion market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, and treatment preferences that help in shaping and driving the 7MM RET Fusion market.
• Market Size of Inhibitors by therapies and indication will be provided

RET Fusion Report Key Strengths

• 11 Years RET Fusion Market Forecast
• The 7MM Coverage
• RET Fusion Competitive Landscape of current and emerging therapies
• RET Fusion Total Addressable patient population
• Drugs Uptake and Key Market Forecast Assumptions
• Approved and Emerging therapy Profiles
• Physician's perspectives/KOL opinions
• Biomarker testing and Patient journey
• Qualitative Analysis (SWOT and Analyst Views)
• RET Fusion Market Size by therapy and indication
• Existing and Future Market Opportunity
• Unmet Needs

FAQs:

• What was the RET Fusion total market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for RET Fusion market growth?
• Which KRAS Inhibitor is going to be the largest contributor by 2034?
• What is the market access and reimbursement scenario of RET Fusion?
• What are the pricing variations among different geographies?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the RET Fusion Market.
• Understand the existing RET Fusion market opportunities and future trends in varying geographies
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility and acceptability of emerging treatment options along with unmet need of current therapies
• Details on report methodology, top indications covered, market assumptions, patient journey and KOLs to strengthen the pharmaceutical companies' development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of RET Fusion

4. Key Events

5. RET Fusion Market Overview At A Glance

• 5.1. Market Share (%) Distribution of RET Fusion By Therapy in 2023
• 5.2. Market Share (%) Distribution of RET Fusion By Therapy in 2034

6. Background And Overview

7. Target Population

8. RET Fusion Marketed Drugs

• 8.1. Key Competitors
• 8.2. Company 1: Product 1
  • 8.2.1. Product Description
  • 8.2.2. Regulatory Milestones
  • 8.2.3. Other Developmental Activities
  • 8.2.4. Ongoing Clinical Development
  • 8.2.5. Safety and Efficacy
• 8.3. Company 2: Product 2
  • 8.3.1. Product Description
  • 8.3.2. Regulatory Milestones
  • 8.3.3. Other Developmental Activities
  • 8.3.4. Ongoing Clinical Development
  • 8.3.5. Safety and Efficacy

9. RET Fusion Emerging Drugs

• 9.1. Key Competitors
• 9.2. Company 1: Product 1
  • 9.2.1. Product Description
  • 9.2.2. Other Development Activities
  • 9.2.3. Clinical Development
    • 9.2.3.1. Clinical Trials Information
  • 9.2.4. Safety and Efficacy
• 9.3. Company 2: Product 2
  • 9.3.1. Product Description
  • 9.3.2. Other Development Activities
  • 9.3.3. Clinical Development
    • 9.3.3.1. Clinical Trials Information
  • 9.3.4. Safety and Efficacy

10. RET Fusion: The 7MM Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Key Market Forecast Assumptions
• 10.4. Total Market Size of RET Fusion in the 7MM
  • 10.4.1. Market Size of RET Fusion By Therapies In the 7MM
  • 10.4.2. Market Size of RET Fusion By Indication In the 7MM
• 10.6. United States Market
  • 10.6.1. Total Market Size of RET Fusion in the United States
  • 10.6.2. Market Size of RET Fusion By Therapies in the United States
• 10.7. EU4 and the UK Market
  • 10.7.1. Total Market Size of RET Fusion in EU4 and the UK
  • 10.7.2. Market Size of RET Fusion By Therapies in EU4 and the UK
• 10.8. Japan Market
  • 10.8.1. Total Market Size of RET Fusion in Japan
  • 10.8.2. Market Size of RET Fusion By Therapies in Japan

11. Unmet Needs

12. SWOT Analysis

13. KOL Views

14. Market Access and Reimbursement

• 14.1. United States
  • 14.1.1. Centre for Medicare & Medicaid Services (CMS)
• 14.2. EU4 and the UK
  • 14.2.1. Germany
  • 14.2.2. France
  • 14.2.3. Italy
  • 14.2.4. Spain
  • 14.2.5. United Kingdom
• 14.3. Japan
  • 14.3.1. MHLW

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. Delveinsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

• Table 1: Target Population in the 7MM (2020-2034)
• Table 2: Marketed Drug Key cross
• Table 3: Product 1, Clinical Trial Description, 2024
• Table 4: Product 2, Clinical Trial Description, 2024
• Table 5: Emerging Drug Key cross
• Table 6: Product 1, Clinical Trial Description, 2024
• Table 7: Product 2, Clinical Trial Description, 2024
• Table 8: Total RET Fusion Market Size in the 7MM (2020-2034)
• Table 9: RET Fusion Market Size by Therapies in the 7MM (2020-2034)
• Table 10: RET Fusion Market Size by Indication in the 7MM (2020-2034)
• Table 11: Total RET Fusion Market Size in the United States (2020-2034)
• Table 12: RET Fusion Market Size by Therapies in the United States (2020-2034)
• Table 13: Total RET Fusion Market Size in EU4 and the UK (2020-2034)
• Table 14: RET Fusion Market Size by Therapies in EU4 and the UK (2020-2034)
• Table 15: Total RET Fusion Market Size in Japan (2020-2034)
• Table 16: RET Fusion Market Size by Therapies in Japan (2020-2034)

List of Figures

• Figure 1: Target Population in the 7MM (2020-2034)
• Figure 2: Total RET Fusion Market Size in the 7MM (2020-2034)
• Figure 3: RET Fusion Market Size by Therapies in the 7MM (2020-2034)
• Figure 4: RET Fusion Market Size by Indication in the 7MM (2020-2034)
• Figure 5: Total RET Fusion Market Size in the United States (2020-2034)
• Figure 6: RET Fusion Market Size by Therapies in the United States (2020-2034)
• Figure 7: Total RET Fusion Market Size in EU4 and the UK (2020-2034)
• Figure 8: RET Fusion Market Size by Therapies in EU4 and the UK (2020-2034)
• Figure 9: Total RET Fusion Market Size in Japan (2020-2034)
• Figure 10: RET Fusion Market Size by Therapies in Japan (2020-2034)